scholarly journals Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry

2019 ◽  
Vol 6 (2) ◽  
pp. 217-230 ◽  
Author(s):  
Leslie R. Harrold ◽  
Heather J. Litman ◽  
Sean E. Connolly ◽  
Evo Alemao ◽  
Sheila Kelly ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
United States ◽  
Tumor Necrosis Factor ◽  
Comparative Effectiveness ◽  
Tumor Necrosis ◽  
The United States ◽  
Tumor Necrosis Factor Inhibitors ◽  
Necrosis Factor

Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists

2006 ◽  
Vol 73 (6) ◽  
pp. 718-724 ◽  
Author(s):  
Khalid M. Kamal ◽  
S. Suresh Madhavan ◽  
Jo Ann Allen Hornsby ◽  
Lesley-Ann Miller ◽  
Jan Kavookjian ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
United States ◽  
Tumor Necrosis Factor ◽  
National Survey ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitors ◽  
Necrosis Factor

Enbrel: The Sting of Success

2017 ◽  
pp. 1-20
Author(s):  
Alicia Löffler ◽  
Geetha P. Krishnan
Keyword(s):  
Rheumatoid Arthritis ◽  
United States ◽  
Decision Making ◽  
Tumor Necrosis Factor ◽  
Effective Treatment ◽  
Tumor Necrosis ◽  
The United States ◽  
Decision Making Process ◽  
Biotechnology Company ◽  
Necrosis Factor

Immunex, a small Seattle biotechnology company, stumbles into a hugely successful and groundbreaking product. Enbrel, a tumor necrosis factor, is immediately recognized as the most effective treatment for rheumatoid arthritis–a $300 billion market in the United States. After almost 20 years of unprofitability, Enbrel is a lifesaver for Immunex. But it could also become the company's worst nightmare. Immunex, after years of being cash starved, has not been able to build production capabilities to satisfy the sudden and massive demand for its drug.To illustrate the decision-making process concerning how and when to build commercialization capabilities in a small biotechnology company. Also, to explore options for reacting to an unexpected demand in a hypercompetitive market.

Sign in / Sign up

Export Citation Format

Share Document